JUL 24, 2020 12:46 PM PDT

A New Biomarker Candidate for Cancer Diagnostics

WRITTEN BY: Jasper Cantrell

One of the best tools in the fight against cancer is diagnostics. In 2018, colorectal cancer was the second most lethal cancer in the world due to a lack of effective diagnostic tools. It is often not caught until it reaches later stages, where treatments are less impactful.

Modern diagnostics identify diseases and their severity by following biomarkers. Biomarkers are genes, proteins, or other factors with abnormal expression levels in diseases compared to healthy tissues. In cancer, this type of diagnostic method has become popular in the research. Future diagnostic tools will be able to identify a disease and identify the best way to treat it.

A recent screening study in colorectal cancer found that the protein transcobalamin 1 is abnormally expressed. This protein has various cellular roles and has been found in high levels in several types of cancer. A team from the Hebei Medical University in China decided to investigate this biomarker candidate to diagnose colorectal cancer.  

The team began by confirming that transcobalamin 1 is overexpressed in colorectal patients versus healthy tissue. Statistical analysis revealed it was strongly associated with a poor prognosis and late stages of colorectal cancer. These observations indicate transcobalamin 1 may act as a good diagnostic marker for colorectal cancer. On top of that, there was a distinct decrease in transcobalamin 1 levels after being treated with chemotherapy.

The team then examined how transcobalamin 1 acted as a tumor promoter. Computational analysis showed that many proteins involved in pro-tumor signaling were upregulated alongside transcobalamin 1. They could not further elaborate, however.

In this study, transcobalamin 1 proved to be a strong candidate for a diagnostic biomarker. It was clearly overexpressed in colorectal cancers, and this expression decreased upon undergoing chemotherapy showing it has potential as a chemosensitivity marker. How it works as a pro-tumor factor remains unknown, however.

The team concludes, “Taken together, we conclude that TCN1 expression is significantly overexpressed in colon cancer and is correlated with advanced pathological features. TCN1 may be a predictor of prognosis and a potential biomarker for predicting chemosensitivity.”

Sources: Nature Scientific Reports, U.S. Food and Drug Administration

About the Author
  • Hey everyone! My name is Jasper and, considering I am pretty new here to Labroots, I figured I would introduce myself. I received my bachelor’s from the University of California at Riverside back in 2016. I started off my career a few years ago with a job at a University over in New York, before moving over into the industry. I'm happy to be writing content for Labroots, and I hope you enjoy it!
You May Also Like
JUL 15, 2020
Cancer
Mortality rate disparities in hospitals with different star ratings
JUL 15, 2020
Mortality rate disparities in hospitals with different star ratings
The Center for Medicare and Medicaid Services' "Star Rating" system compares the quality of care of hospit ...
JUL 24, 2020
Cancer
Are you sunscreening your children the right way?
JUL 24, 2020
Are you sunscreening your children the right way?
A new national poll suggests that parents are not using the best sunscreen application practices to protect their childr ...
AUG 21, 2020
Immunology
Cancer Feels the STING
AUG 21, 2020
Cancer Feels the STING
Researchers have discovered a protein that can amplify immune reactions against tumors. The stimulator of interferon gen ...
AUG 26, 2020
Cancer
NAP-6: A Potential Candidate for the Treatment of Breast Cancer
AUG 26, 2020
NAP-6: A Potential Candidate for the Treatment of Breast Cancer
The body is an amazing and complex system of pathways, all working together in harmony. However, cancer can quickly disr ...
SEP 02, 2020
Cancer
Does Adjuvant Chemotherapy Really Help in a Rare Signet-ring Cell Carcinoma
SEP 02, 2020
Does Adjuvant Chemotherapy Really Help in a Rare Signet-ring Cell Carcinoma
For many rare diseases, there is a lack of a “standard” treatment options. This is more prevalent in diverse ...
SEP 14, 2020
Cancer
MiR-107 and Its Role in Radiosensitivity in Prostate Cancer
SEP 14, 2020
MiR-107 and Its Role in Radiosensitivity in Prostate Cancer
It is often unknown whether a patient will respond to a treatment until it is in full swing. New research is attempting ...
Loading Comments...